CN111214662B - Nlrp3炎性小体的抑制剂在制备治疗垂体腺瘤的药物中的应用及治疗垂体腺瘤的药物 - Google Patents
Nlrp3炎性小体的抑制剂在制备治疗垂体腺瘤的药物中的应用及治疗垂体腺瘤的药物 Download PDFInfo
- Publication number
- CN111214662B CN111214662B CN202010133472.XA CN202010133472A CN111214662B CN 111214662 B CN111214662 B CN 111214662B CN 202010133472 A CN202010133472 A CN 202010133472A CN 111214662 B CN111214662 B CN 111214662B
- Authority
- CN
- China
- Prior art keywords
- pituitary
- adenoma
- nlrp3
- prolactin
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 108091008099 NLRP3 inflammasome Proteins 0.000 title claims abstract description 21
- 239000003112 inhibitor Substances 0.000 title claims abstract description 14
- 208000007913 Pituitary Neoplasms Diseases 0.000 title abstract description 33
- 201000005746 Pituitary adenoma Diseases 0.000 title abstract description 21
- 206010061538 Pituitary tumour benign Diseases 0.000 title abstract description 21
- 208000021310 pituitary gland adenoma Diseases 0.000 title abstract description 21
- 238000002360 preparation method Methods 0.000 title description 3
- 229940127107 NLRP3 inflammasome inhibitor Drugs 0.000 claims abstract description 9
- 108010057464 Prolactin Proteins 0.000 claims description 85
- 102000003946 Prolactin Human genes 0.000 claims description 85
- 229940097325 prolactin Drugs 0.000 claims description 85
- 208000003200 Adenoma Diseases 0.000 claims description 59
- 206010001233 Adenoma benign Diseases 0.000 claims description 51
- 101150061038 NLRP3 gene Proteins 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- LFQQNXFKPNZRFT-UHFFFAOYSA-M sodium 1,2,3,5,6,7-hexahydro-s-indacen-4-ylcarbamoyl-[4-(2-hydroxypropan-2-yl)furan-2-yl]sulfonylazanide Chemical group [Na+].CC(C)(O)c1coc(c1)S(=O)(=O)[N-]C(=O)Nc1c2CCCc2cc2CCCc12 LFQQNXFKPNZRFT-UHFFFAOYSA-M 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 10
- HUUSXLKCTQDPGL-UHFFFAOYSA-N 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(2-hydroxypropan-2-yl)furan-2-yl]sulfonylurea Chemical group CC(C)(O)C1=COC(S(=O)(=O)NC(=O)NC=2C=3CCCC=3C=C3CCCC3=2)=C1 HUUSXLKCTQDPGL-UHFFFAOYSA-N 0.000 abstract description 9
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 abstract description 6
- 229960005342 tranilast Drugs 0.000 abstract description 6
- 229940122390 Inflammasome inhibitor Drugs 0.000 abstract description 4
- 230000001817 pituitary effect Effects 0.000 description 68
- 241000700159 Rattus Species 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 35
- 102000004169 proteins and genes Human genes 0.000 description 31
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 29
- 229960005309 estradiol Drugs 0.000 description 29
- 229930182833 estradiol Natural products 0.000 description 29
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 28
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 28
- 238000001262 western blot Methods 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 239000013592 cell lysate Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 6
- 229960002802 bromocriptine Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 238000011813 knockout mouse model Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 101000845237 Cereibacter sphaeroides Tryptophan-rich sensory protein Proteins 0.000 description 4
- 101800000414 Corticotropin Proteins 0.000 description 4
- 101000845206 Homo sapiens Putative peripheral benzodiazepine receptor-related protein Proteins 0.000 description 4
- 101000845233 Homo sapiens Translocator protein Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 4
- 102100031269 Putative peripheral benzodiazepine receptor-related protein Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- GDFGTRDCCWFXTG-SCTDSRPQSA-N (3r,4ar,10as)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2h-benzo[g]quinoline Chemical compound C1=CC=C2C[C@@H]3N(CCC)C[C@H](NS(=O)(=O)N(CC)CC)C[C@H]3CC2=C1O GDFGTRDCCWFXTG-SCTDSRPQSA-N 0.000 description 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
- 102000006771 Gonadotropins Human genes 0.000 description 3
- 108010086677 Gonadotropins Proteins 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000011923 Thyrotropin Human genes 0.000 description 3
- 108010061174 Thyrotropin Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002622 gonadotropin Substances 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 208000010916 pituitary tumor Diseases 0.000 description 3
- 229960000924 quinagolide Drugs 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical class O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 2
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 2
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 2
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 2
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000014993 Pituitary disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229960004596 cabergoline Drugs 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229950002007 estradiol benzoate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002710 gonadal effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000001287 Galactorrhea Diseases 0.000 description 1
- 206010017600 Galactorrhoea Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 101000687509 Rattus norvegicus Prolactin Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010068268 Tumour compression Diseases 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000008195 breast development Effects 0.000 description 1
- 210000000711 cavernous sinus Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- VTAOWWAFBSFWSG-UHFFFAOYSA-N ethyl 2-[(2-chlorophenyl)methyl]prop-2-enoate Chemical compound CCOC(=O)C(=C)CC1=CC=CC=C1Cl VTAOWWAFBSFWSG-UHFFFAOYSA-N 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000001756 lactotroph Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 229960001511 pergolide mesylate Drugs 0.000 description 1
- UWCVGPLTGZWHGS-ZORIOUSZSA-N pergolide mesylate Chemical compound CS(O)(=O)=O.C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 UWCVGPLTGZWHGS-ZORIOUSZSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010133472.XA CN111214662B (zh) | 2020-02-28 | 2020-02-28 | Nlrp3炎性小体的抑制剂在制备治疗垂体腺瘤的药物中的应用及治疗垂体腺瘤的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010133472.XA CN111214662B (zh) | 2020-02-28 | 2020-02-28 | Nlrp3炎性小体的抑制剂在制备治疗垂体腺瘤的药物中的应用及治疗垂体腺瘤的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111214662A CN111214662A (zh) | 2020-06-02 |
CN111214662B true CN111214662B (zh) | 2022-03-22 |
Family
ID=70826850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010133472.XA Active CN111214662B (zh) | 2020-02-28 | 2020-02-28 | Nlrp3炎性小体的抑制剂在制备治疗垂体腺瘤的药物中的应用及治疗垂体腺瘤的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111214662B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104258398A (zh) * | 2014-10-14 | 2015-01-07 | 中国科学技术大学 | Drd1及其激动剂在制备治疗nlrp3炎症小体相关炎症性疾病药物中的用途 |
WO2015039083A2 (en) * | 2013-09-16 | 2015-03-19 | St. Jude Children's Research Hospital | Methods for overcoming glucocorticoid resistance and for determining glucocorticoid resistance potential in cancer |
CN109071535A (zh) * | 2016-04-19 | 2018-12-21 | 先天肿瘤免疫公司 | Nlrp3调节剂 |
CN109196118A (zh) * | 2015-11-04 | 2019-01-11 | 艾德拉药物股份有限公司 | 用于抑制nlrp3基因表达的组合物及其用途 |
CN110151742A (zh) * | 2019-05-22 | 2019-08-23 | 王雄 | 大麦芽碱在制备治疗垂体瘤药物中的用途 |
CN110575453A (zh) * | 2019-10-30 | 2019-12-17 | 中国科学技术大学 | Ns1619在抑制nlrp3炎症小体活化中的应用 |
-
2020
- 2020-02-28 CN CN202010133472.XA patent/CN111214662B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015039083A2 (en) * | 2013-09-16 | 2015-03-19 | St. Jude Children's Research Hospital | Methods for overcoming glucocorticoid resistance and for determining glucocorticoid resistance potential in cancer |
CN104258398A (zh) * | 2014-10-14 | 2015-01-07 | 中国科学技术大学 | Drd1及其激动剂在制备治疗nlrp3炎症小体相关炎症性疾病药物中的用途 |
CN109196118A (zh) * | 2015-11-04 | 2019-01-11 | 艾德拉药物股份有限公司 | 用于抑制nlrp3基因表达的组合物及其用途 |
CN109071535A (zh) * | 2016-04-19 | 2018-12-21 | 先天肿瘤免疫公司 | Nlrp3调节剂 |
CN110151742A (zh) * | 2019-05-22 | 2019-08-23 | 王雄 | 大麦芽碱在制备治疗垂体瘤药物中的用途 |
CN110575453A (zh) * | 2019-10-30 | 2019-12-17 | 中国科学技术大学 | Ns1619在抑制nlrp3炎症小体活化中的应用 |
Non-Patent Citations (4)
Title |
---|
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases;Rebecca C et al.;《Nat Med》;20150216;第21卷(第3期);第248-255页 * |
Microglial NLRP3 inflammasome activation-mediated inflammation promotes prolactinoma development;Xiong Wang et al.;《Endocr Relat Cancer》;20210610;第28卷(第7期);第433-448页 * |
Mitochondrial Dysfunction Pathway Networks and Mitochondrial Dynamics in the Pathogenesis of Pituitary Adenomas;Na Li et al.;《Front Endocrinol (Lausanne)》;20191009;第10卷;第690页 * |
Role of the NLRP3 inflammasome in cancer;Maryam M et al.;《Mol Cancer》;20181117;第17卷(第1期);第158页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111214662A (zh) | 2020-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109640991A (zh) | 治疗前列腺癌的方法 | |
WO2020233138A1 (zh) | 大麦芽碱在制备治疗垂体瘤药物中的用途 | |
JP2021106625A (ja) | Il−34アンチセンスオリゴヌクレオチドおよびその使用方法 | |
CN111214662B (zh) | Nlrp3炎性小体的抑制剂在制备治疗垂体腺瘤的药物中的应用及治疗垂体腺瘤的药物 | |
CN107126445A (zh) | 粪菌移植在治疗帕金森病方面的应用 | |
CN106511347A (zh) | 氯化两面针碱在制备预防/治疗脓毒症药物中的应用 | |
CN111803489B (zh) | 含笑内酯及其衍生物在垂体腺瘤治疗中的应用 | |
CN115998723A (zh) | 莽草酸在制备预防和/或治疗水产动物白斑综合征药物中的应用 | |
CN112891360B (zh) | 脱氧土大黄苷的新用途 | |
CN106635999B (zh) | Mmhrl1转基因小鼠肝肿瘤细胞系的建立及应用 | |
Li et al. | Effect of procyanidins from Pinus koraiensis bark on growth inhibition and expression of PCNA and TNF-[alpha][alpha] in mice with U14 cervical cancer | |
CN101507747B (zh) | 黄芪总皂苷氯化钠注射液的制备方法 | |
CN109091539B (zh) | 一种中药提取物组合物、其制备方法及其应用 | |
CN105251006B (zh) | Tlr3抑制剂在制备治疗可卡因成瘾的药物中的用途 | |
CN104622874B (zh) | Ccr4拮抗剂在抑制癌生长及转移中的应用 | |
CN1682969A (zh) | 一种药物组合物及其制备方法和质量控制方法 | |
US20070207198A1 (en) | Use Of N-Acety1-D-Glucosamine In The Manufacture Of Medicaments For Anti-Tumors And Anti-Metastasis | |
CN105879033B (zh) | GnRH Ⅱ型拮抗剂在抑制孕激素耐药子宫内膜癌细胞增殖中的应用 | |
Tang et al. | Effect of dioscorea pills on immunity of mice receiving chemotherapy for ovarian cancer | |
Wei et al. | Paeonol ameliorates hippocampal neuronal damage by inhibiting GRM5/GABBR2/β-arrestin2 and activating the cAMP-PKA signaling pathway in premenstrual irritability rats | |
WO2022143984A1 (zh) | 一种用于治疗癌症的药物组合物及其制备方法和用途 | |
CN112587518B (zh) | 鸦胆子苦醇药物组合物及其用途 | |
CN110075131A (zh) | 寨卡病毒减毒株在治疗脑胶质瘤中的应用 | |
CN104288185B (zh) | 一种治疗小儿湿疹的多糖核酸药物组合物的制备方法 | |
CN114452288B (zh) | 组合物在脑胶质瘤治疗中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220307 Address after: 430000 room 141, floor 1-5, building 6, Gaonong Biological Park comprehensive service area (II), zone B, No. 888, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, Hubei Province (Wuhan area of free trade zone) Applicant after: Wuhan Yefeng Biotechnology Co.,Ltd. Address before: 430000 No. 1, Huangjiahu Huanhu West Road, Qingling Township, Hongshan District, Wuhan City, Hubei Province Applicant before: Wang Xiong |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240308 Address after: No. 241, pengliuyang Road, Wuchang District, Wuhan City, Hubei Province 430000 Patentee after: WUHAN THIRD Hospital Country or region after: China Address before: 430000 room 141, floor 1-5, building 6, Gaonong Biological Park comprehensive service area (II), zone B, No. 888, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, Hubei Province (Wuhan area of free trade zone) Patentee before: Wuhan Yefeng Biotechnology Co.,Ltd. Country or region before: China |